Capecitabine and Hand-foot Syndrome: A Case Report

Title:Capecitabine and Hand-foot Syndrome: A Case Report

Volume: 23 Issue: 1

Author(s): Praveen Kumar Uppala, Anjaly Mary Varghese, Sree Sudha Tanguturi Yella*, Hemasri Velmurugan, Pugazhenthan Thangaraju and Kota Shesha Brahma Shree Krishna Sasanka

Affiliation:

• Department of Pharmacology, All India Institute of Medical Sciences, Deoghar, Jharkhand, India

Keywords: Capecitabine (Xeloda), hand-foot syndrome (HFS), erythema, palmoplantar erythrodysesthesia, mucinous adenocarcinoma of sigmoid colon, adenocarcinoma of the stomach, WHO causality assessment, naranjo causality assessment.

Abstract: Capecitabine, a prodrug of 5-fluorouracil, is an FDA-approved drug for adjuvant treatment of colon, metastatic colorectal, and breast cancer. A variety of mucocutaneous adverse effects has been recognized with capecitabine. The pathogenesis of such manifestations still remains an enigma though various theories have been proposed. Here, we report two such cases. A 59-year-old female with carcinoma of the sigmoid colon on palliative therapy developed localized cutaneous hyperpigmentation of the palms and soles secondary to capecitabine in her 2nd cycle. Another case was of a 42-year-old female with stomach adenocarcinoma, who developed similar adverse effects after administration of capecitabine in her 4th cycle. Since these drugs have been widely used in recent years due to their relative ease in administration, the relative unawareness of Hand-foot syndrome (HFS) caused due to this drug makes it a prudent topic to be reported.

Cite this article as:

Uppala Kumar Praveen, Varghese Mary Anjaly, Yella Sudha Tanguturi Sree*, Velmurugan Hemasri, Thangaraju Pugazhenthan and Krishna Sasanka Brahma Shree Kota Shesha, Capecitabine and Hand-foot Syndrome: A Case Report, Infectious Disorders - Drug Targets 2023; 23 (1) : e140622205973 . https://dx.doi.org/10.2174/1871526522666220614162117